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ABSTRACT
Purpose: Subsets of pituitary tumors exhibit an aggressive clinical courses 
and recur despite surgery, radiation, and chemotherapy. Because modulation of 
the immune response through inhibition of T-cell checkpoints has led to durable 
clinical responses in multiple malignancies, we explored whether pituitary adenomas 
express immune-related biomarkers that could suggest suitability for immunotherapy. 
Specifically, programmed death ligand 1 (PD-L1) has emerged as a potential 
biomarker whose expression may portend more favorable responses to immune 
checkpoint blockade therapies. We thus investigated the expression of PD-L1 in 
pituitary adenomas. 
Methods: PD-L1 RNA and protein expression were evaluated in 48 pituitary 
tumors, including functioning and non-functioning adenomas as well as atypical and 
recurrent tumors. Tumor infiltrating lymphocyte populations were also assessed by 
immunohistochemistry. 
Results: Pituitary tumors express variable levels of PD-L1 transcript and protein. 
PD-L1 RNA and protein expression were significantly increased in functioning (growth 
hormone and prolactin-expressing) pituitary adenomas compared to non-functioning 
(null cell and silent gonadotroph) adenomas. Moreover, primary pituitary adenomas 
harbored higher levels of PD-L1 mRNA compared to recurrent tumors. Tumor 
infiltrating lymphocytes were observed in all pituitary tumors and were positively 
correlated with increased PD-L1 expression, particularly in the functional subtypes. 
Conclusions: Human pituitary adenomas harbor PD-L1 across subtypes, with 
significantly higher expression in functioning adenomas compared to non-functioning 
adenomas. This expression is accompanied by the presence of tumor infiltrating 
lymphocytes. These findings suggest the existence of an immune response to pituitary 
tumors and raise the possibility of considering checkpoint blockade immunotherapy 
in cases refractory to conventional management.
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INTRODUCTION
Pituitary tumors are the second most common 
intracranial neoplasms, comprising 10-15% of diagnosed 
brain tumors [1, 2]. Some pituitary tumors are considered 
“functioning” and liberate physiologic hormones 
to a pathologic degree to manifest as one of several 
classic endocrinologic syndromes. Specifically, tumors 
producing growth hormone (GH) or adrenocorticotropic 
hormone (ACTH) are associated with significant 
systemic medical morbidity. In contrast,  other pituitary 
tumors are hormonally silent (non-functioning) but may 
compress adjacent neurovascular structures during growth, 
conferring degrees of visual loss, pituitary dysfunction, 
and cranial neuropathies. Although often cured by 
surgery alone or controlled medically, as in the case of 
most prolactin-secreting tumors, recurrence rates are not 
insignificant. In a large cohort of patients followed for 10 
years after transsphenoidal surgery, rates of recurrence 
across tumor subtypes varied between 6-25% [3]. In 
the recurrent setting, adjuvant medical treatments in 
functioning and non-functioning tumors are only variably 
effective in durable tumor control, and radiotherapy 
may be limited by proximity to the optic nerves. Other 
subclasses of pituitary tumors that may be difficult to 
manage include atypical adenomas and those that invade 
the cavernous sinus and surround one or both cavernous 
carotid arteries. Overall, there are a limited number of 
adjuvant treatment options for clinically challenging 
pituitary tumors. 
The use of immune-based therapies has led to 
durable clinical responses in patients with a range of 
systemic cancers [4-7]. In particular, treatments that block 
T cell “checkpoints”—such as the negative regulator 
proteins cytotoxic T-lymphocyte-associated protein 
4 (CTLA-4) and programmed cell death 1 (PD-1)/
programmed death ligand-1 (PD-L1)—unleash tumor-
specific immune responses and are now FDA-approved 
to treat melanoma, lung cancer, and renal cell carcinoma. 
PD-1 is inducible on tumor infiltrating lymphocytes [8-11], 
while one of its ligands, PD-L1, may be overexpressed by 
tumor cells or antigen-presenting cells. The binding of PD-
L1 to PD1 represents an “immune checkpoint” in that it 
impairs the function of activated lymphocytes in peripheral 
tissues [12-16], providing a potential mechanism by 
which tumors may evade the immune response [14, 17, 
18]. Importantly, in several cancers, PD-L1 expression 
is positively correlated with improved responses to anti-
PD-1/PD-L1 blockade [5, 18], though immunotherapy has 
also been shown to benefit of a subset of patients whose 
tumors do not express PD-L1 [19, 20]. Recently, PD-L1 
was found to be highly expressed in both glioblastoma 
[21, 22] as well as high-grade meningioma [23], raising 
the possibility of checkpoint inhibition in central nervous 
system tumors, for which clinical trials are ongoing. 
Thus, due to the dearth of adjuvant therapies for 
pituitary tumors refractory to conventional treatments 
and the recent success of checkpoint blockade 
immunotherapies in cancer, we investigated the expression 
of PD-L1 in a range of human pituitary tumors. We 
determined the level of expression first by RNAscope 
analysis, and then confirmed PD-L1 protein expression 
by immunohistochemistry. Lastly, we characterized the 
immune cell infiltrates in these tumors. 
RESULTS
Pituitary adenomas express variable levels of PD-
L1
We first assessed PD-L1 expression profiles in 
pituitary tumors by investigating mRNA and protein levels 
across pituitary adenomas. We used RNAscope in situ 
hybridization to detect PD-L1 mRNA and IHC to assess 
PD-L1 protein expression. Across all pituitary adenomas, 
variable expression of PD-L1 was observed (Figure 1), 
with a 10-fold difference in protein levels and a 5-fold 
difference across mRNA signals. 
PD-L1 mRNA and protein levels are increased 
in functioning adenomas compared to non-
functioning adenomas
We next explored the relationship between PD-
L1 expression and subclasses of pituitary adenomas. 
Comparison of functioning (GH and PRL expressing, n = 
28) and non-functioning (null cell and silent gonadotroph, 
n = 20) adenomas revealed significantly higher mRNA 
levels in the functioning tumors (p = 0.023, Figure 2A-
B). Consistent with PD-L1 transcript levels, functioning 
adenomas harbored statistically higher PD-L1 protein 
expression compared to non-functioning adenomas (p 
= 0.039, Figure 2C-D). However, little correlation was 
observed between PD-L1 mRNA and protein levels 
at an individual sample level (Supplementary Figure 
1). Somatotroph adenomas and mammosomatotroph 
adenomas did not vary significantly in their PD-L1 
expression.
 PD-L1 is expressed in recurrent and atypical 
adenomas
We next investigated PD-L1 levels in recurrent and 
atypical pituitary adenomas, classes of tumors that can be 
challenging to manage with existing treatment strategies. 
PD-L1 transcript, but not protein levels, was significantly 
elevated in primary (n = 34) compared to recurrent (n 
= 14) pituitary adenomas (p = 0.0048 for transcript, p 
= 0.316 for protein, Figure 3). Atypical tumors were 
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classified by WHO criteria, as adenomas with excessive 
p53 immunoreactivity or increased mitotic activity [1]. 
While PD-L1 mRNA and protein are expressed, they did 
not vary significantly between adenomas with typical 
(n = 37) or atypical (n = 11) status (p = 0.54 and 0.21, 
respectively, Figure 4). 
The MIB-1 proliferative index has been shown to 
independently predict tumor recurrence or invasiveness 
and is elevated in atypical adenomas [26, 27]. We 
further examined the expression of PD-L1 in adenomas 
with MIB-1 ≤ 3% (n = 20) or MIB-1 > 3% (n = 28). No 
significant correlation was observed between PD-L1 
mRNA or protein expression and MIB-1 index (Figure 5). 
Characterization of the immune infiltrate of 
pituitary tumors in tissue specimens
Having characterized PD-L1 expression in our 
cohort of pituitary tumors, we investigated the presence 
of lymphocytic infiltrate in these specimens. We stained 
Figure 1: PD-L1 expression across pituitary adenomas. Quantification of PD-L1 mRNA (left y-axis) and protein (right y-axis) 
levels across all pituitary tumors in the cohort reveals diversity in expression. Samples within each scatter plot are divided into quartiles, 
centered around the median. 
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Figure 2: PD-L1 mRNA and protein expression in functioning and non-functioning pituitary tumors. A. Quantification 
of PD-L1 RNAscope staining in functioning (n = 28) and non-functioning (n = 20) pituitary adenomas. B. In situ hybridization of PD-L1 
mRNA using a PD-L1-specific RNAscope probe in a functioning (GH) and a non-functioning (null cell) pituitary tumor. C. Quantification 
of PD-L1 IHC staining in functioning and non-functioning pituitary adenomas. D. IHC staining of PD-L1 protein in a functioning (GH) and 
a non-functioning (null cell) pituitary adenoma. *p < 0.05, scale bar 50µm.
Figure 3: PD-L1 mRNA and protein expression in primary and recurrent pituitary tumors. A. Quantification of PD-L1 
RNAscope staining in primary (n = 34) and recurrent (n = 14) pituitary adenomas. B. RNAscope staining of PD-L1 mRNA in a primary 
and a recurrent pituitary tumor. C. Quantification of PD-L1 IHC staining in primary and recurrent pituitary adenomas. D. IHC staining of 
PD-L1 protein in a primary and a recurrent pituitary adenoma. *p < 0.05, scale bar 50 µm.
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TMAs with antibodies targeting a pan-lymphocyte marker 
(CD45), T cell markers (CD3, CD4, CD8) and the immune 
regulatory receptor PD-1. An analysis of all tumors taken 
together shows variable CD3, CD4, CD8, CD45, and PD-1 
expression (Figure 6). 
When analyzed by subclass of tumor (Figure 7), 
both CD3+ and CD4+ populations were significantly 
increased in functioning adenomas compared to non-
functioning adenomas (p = 0.019 and p = 0.0001, 
respectively). All lymphocytic infiltrate markers appeared 
higher in adenomas with an elevated proliferative index, 
with a significantly increased expression in CD45+ cell 
infiltrates in adenomas with high (MIB-1 > 3%) compared 
to low (MIB-1 ≤ 3%) proliferative indices (p = 0.0093). 
Furthermore, CD3+, CD4+, and CD45+ cells trended to 
a higher expression in atypical adenomas compared to 
typical adenomas. PD-1 was significantly increased in 
non-functioning adenomas (p = 0.0018) and those with 
elevated proliferative indices (p = 0.003), while being 
comparable in primary and recurrent tumors. 
DISCUSSION
Substantial work over the last fifteen years has 
begun to clarify the complex relationship between the 
immune system and cancer. Specifically, the “cancer 
immunoediting hypothesis” articulates that tumors 
dynamically evolve to evade immune responses in order 
to grow progressively [28]. This shared cancer phenotype 
of immunoevasion is recognized as a “hallmark of cancer” 
[29]. Capitalization on the molecular basis of immune 
regulation has led to the application of checkpoint 
blockade immunotherapy in several tumor types, with 
durable clinical responses in some patients with advanced 
metastatic cancer. 
We investigated several immunological parameters 
in pituitary tumors with the goal of exploring new 
therapeutic avenues for treatment-refractory tumors. 
In particular, the location of the pituitary gland outside 
the blood brain barrier may render systemic therapies 
more effective. Using in situ RNA hybridization and 
Figure 4: PD-L1 mRNA and protein expression in typical and atypical pituitary tumors. A. Quantification of PD-L1 
RNAscope staining in typical (n = 37) and atypical (n = 11) pituitary adenomas. B. RNAscope staining of PD-L1 mRNA in a typical and 
an atypical pituitary tumor. C. Quantification of PD-L1 IHC staining in typical and atypical pituitary adenomas. D. IHC staining of PD-L1 
protein in a typical and an atypical pituitary tumor. Scale bar 50µm.
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immunohistochemistry, we assessed the expression of the 
immunoregulatory checkpoint molecule PD-L1 as well 
as the infiltrating lymphocyte population within a broad 
range of pituitary tumors. Together, our findings are the 
first to demonstrate expression of both PD-L1 mRNA 
and protein in pituitary tumors irrespective of tumor 
hormone secretion, proliferative index, aggressiveness 
level, or recurrence status. Previous studies have reported 
the presence of T-cell enriched populations of tumor 
infiltrating lymphocytes in pituitary adenomas [30, 
31]. Functional subtypes (e.g. GH adenomas) appear to 
demonstrate greater degrees of lymphocyte infiltration 
than non-functional tumors [32]. In our study, functional 
pituitary tumors exhibited more frequent lymphocytic 
infiltration than non-functional tumors, consistent with 
previous observations [31]. Ongoing work is directed at 
expanding our analysis in order to increase our statistical 
power to clarify the tumor-to-tumor differences in immune 
cell subsets and cell surface activation markers. 
The interaction between PD-L1 and the PD-1 
receptor on T cells leads to an inhibitory signal that 
constrains the function of activated lymphocytes 
[33]. Thus, PD-L1 overexpression is postulated to be 
a strategy employed by tumors to evade anti-tumor 
immune responses. Several mechanisms underlying PD-
L1 upregulation have been described that can broadly 
be considered either “intrinsic” or “extrinsic” in nature. 
Specifically, increased PD-L1 expression appears to be 
driven by a number of cell-intrinsic programs—in the 
setting of PTEN loss in malignant brain tumors [21], 
activating EGFR mutations in non-small cell lung cancer 
[34], and increased STAT3 and AP-1 transcriptional 
activation in BRAF-mutant melanomas resistant to 
BRAF inhibition [35]. Alternatively, cytokines produced 
in the tumor microenvironment may also drive PD-
L1 expression in an “extrinsic” manner. For instance, 
interferon-gamma secretion by lymphocytes leads to 
target cell PD-L1 upregulation. This finding stimulated the 
Figure 5: Correlation between MIB-1 proliferative index and PD-L1 expression in pituitary adenomas. A. Quantification 
of PD-L1 RNAscope staining in pituitary adenomas with different proliferation indices. B. RNAscope staining of PD-L1 mRNA in pituitary 
adenomas with different proliferation indices. C. Quantification of PD-L1 IHC staining in pituitary adenomas with different proliferation 
indices. D. IHC staining of PD-L1 protein in pituitary adenomas with different proliferation indices. Scale bar 50µm.
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concept of “adaptive immune resistance” whereby tumor 
cells responding to anti-tumor lymphocytes may increase 
the expression of inhibitory molecules such as PD-L1 [16]. 
Concomitant presence of lymphocyte populations and PD-
L1 expressing cells in pituitary adenomas, as shown in 
this study, suggests that pituitary tumors might invoke 
such an adaptive immune resistance mechanism, although 
the possibility of concomitant intrinsic programs remain. 
Further work will be needed to determine whether these, 
or other novel, regulatory pathways converge on PD-L1 
overexpression in pituitary tumors. 
The selective increase in PD-L1 expression observed 
in functional pituitary tumors raises a number of future 
areas of investigation. Our group has characterized the 
genomic landscape of a broad range of pituitary adenomas 
including functional and non-functional tumors, and there 
do not appear to be recurrent alterations in some of the 
genes, such as PTEN and EGFR, that have been implicated 
in PD-L1 upregulation in other tumor types. However, we 
observed significant differences in broad copy number 
alterations in the functional subset compared to other 
pituitary tumors. Ongoing work is directed at exploring 
whether (a) other shared signaling pathway components 
downstream of PTEN and EGFR alterations may be more 
Figure 6: Immune infiltrate markers and PD-1 expression across pituitary adenomas. Pituitary tumors express variable 
levels of A. lymphocytic markers, including the T-lymphocyte markers CD3, CD4, and CD8, as well as the pan-lymphocyte marker CD45, 
and B. PD-1. Protein expression is normalized to intensity/cell surface area. Samples within each scatter plot are divided into quartiles, 
centered around the median. 
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activated in functional tumors; (b) there are recurrent 
copy number alterations in pathway components that 
may be relevant to PD-L1 expression or regulation; and 
(c) a globally altered copy number state itself may be an 
activator of PD-L1 upregulation. 
The clinical success of PD-1/PD-L1 blockade has 
generated enthusiasm in exploring the spectrum of tumor 
types that may respond to checkpoint inhibition. However, 
although durable responses to PD-1/PD-L1 therapies have 
been observed in a range of cancers including melanoma, 
non-small cell lung cancer, and renal cell carcinoma [36], 
reliable biomarkers to predict who will respond to immune 
blockade are still lacking. Presently, substantial work has 
centered on the use of PD-L1 as a predictive biomarker 
Figure 7: Characterization of the immune infiltrate of pituitary tumors in tissue specimens. A. Pan-lymphocyte marker 
CD45 expression in pituitary tumors classified according to tumor function, recurrence status, aggressiveness level, or proliferation status. 
B. CD3+ T lymphocyte, C. CD4+ T lymphocyte, D. CD8+ T lymphocyte and E. PD-1 expression in pituitary tumors. *p < 0.05.
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[37], which motivated our analysis of its expression in 
pituitary tumors. Initial studies showed patients whose 
tumors exhibited PD-L1 expression demonstrated 
improved clinical responses compared to patients with PD-
L1 negative tumors when treated with the ant-PD-1 drug, 
nivolumab [5] or pembrolizumab [38]. Moreover, a recent 
study in which patients with urothelial cancer were treated 
with the anti-PD-L1 agent, atezolizumab, showed that PD-
L1 expression on tumor immune infiltrate was associated 
with improved clinical responses [6]. Intriguingly, both 
high-grade meningioma and high-grade glioma show 
increased rates of PD-L1 expression, suggesting that 
PD-L1 may correlate both with tumor aggressiveness 
and potential response to therapy [39, 40]. However, 
additional studies have shown that patients with PD-L1 
negative tumors may also exhibit clinical responses to 
anti-PD-1 therapies [41, 42]. Recent work has highlighted 
the complex regulation of PD-L1 levels, with post-
translational modifications playing a substantial role in 
modulating protein levels [43]. Furthermore, there appears 
to be large assay-to-assay variability in the assessment 
of PD-L1 levels, complicating efforts to use expression 
as a pre-requisite for trial enrollment [20]. Our current 
understanding of the relationship between observed PD-
L1 levels and response to immunotherapy is incomplete, 
and this remains an active area of investigation across a 
variety of disciplines. Of note, immunotherapy has been 
associated with treatment-related hypophysitis, which may 
be especially relevant in patients with pituitary tumors 
who are already vulnerable to tumor-related pituitary 
dysfunction [44]. 
Other groups have attempted to stratify tumors by 
the presence of tumor infiltrating lymphocytes and PD-
L1 and have used these parameters to create 4 tumor 
types—i.e, TIL+PD-L1+, TIL-PD-L1+, TIL+PD-L1-, 
and TIL-PD-L1- [45, 46]. There is growing support that 
“TIL+PD-L1+” tumors may have the best chance to respond 
to checkpoint immunotherapy. Thus, in our dataset, it is 
possible that functional and primary adenomas—in which 
there is high PD-L1 as well as increased T cells—may be 
particularly responsive to anti- PD-L1 therapy. In contrast, 
slowly proliferative pituitary tumors—in which there are 
decreased T cells that do not express PD-1, lower PD-L1 
expression, and may be anergic or hypoactive—may be 
less responsive. In other CNS tumors, the presence of 
tumor infiltrating lymphocytes (TILs) has been correlated 
with improved survival in several malignancies, including 
gliomas, and is being examined as a potential prognostic 
biomarker. We anticipate that intracranial tumors may 
actually harbor distinct immunologic microenvironments 
depending on location—e.g., extradural or intradural, 
proximity to commissural organs, and such—and therefore 
additional work is needed to understand how distinct 
intracranial compartments differ. Ultimately, although 
tumor cell PD-L1 expression may predict clinical response 
to anti-PD-1/PD-L1 therapy, it is clear that additional work 
is needed to clarify the full scope of its predictive power as 
well as the contributions of other in situ parameters. 
MATERIALS AND METHODS
Sample selection and preparation
Formalin-fixed, paraffin-embedded human pituitary 
tumor specimens were collected from the Department 
of Pathology, Brigham and Women’s Hospital, with 
corresponding clinical records and pathology reports. 
Hematoxylin and eosin stained sections corresponding 
to each tumor were reviewed by two neuropathologists 
(MA, SS) for selection of specimens with greater than 
70% estimated tumor purity. 48 tumors (with duplicate 
cores for most specimens, spanning 94 samples total) 
were compiled in tissue microarray (TMA) format for 
subsequent analysis. The study was approved by the 
Institutional Review Boards of Brigham and Women’s 
Hospital and Dana Farber Cancer Institute, Harvard 
Medical School. 
Growth hormone (GH) and prolactin (PRL) 
secreting tumors were classified as functioning. Only two 
ACTH-expressing adenomas were in the cohort and were 
excluded from analysis. Null cell adenomas and silent 
gonadotroph adenomas were classified as nonfunctioning. 
RNAscope in situ hybridization
PD-L1 transcript levels were detected using 
RNAscope 2.0 HD brown detection kit (Advanced 
Cell Diagnostics, Hayward, CA). A custom-designed 
RNAscope probe (courtesy of Santagata laboratory) was 
used to stain the pituitary adenoma TMA. As described 
previously [23], 5 μm paraffin-embedded TMA sections 
were baked and deparaffinized, and then boiled with 
pretreatment reagent for 15 minutes. Protease digestion 
was performed at 40ºC for 30 minutes, followed by 
hybridization for 2 hours at 40ºC with Probe-Hs-PDL1-v2 
(Advanced Cell Diagnostics, Hayward, CA). The signal 
was visualized with 3,3’-Diaminobenzidine (DAB) 
and cell nuclei were counterstained with hematoxylin. 
Probe-DapB (Advanced Cell Diagnostics, Hayward, 
CA) and Probe-Hs-PPIB (Advanced Cell Diagnostics, 
Hayward, CA) were used as negative and positive control, 
respectively. All slides were digitally scanned using Carl 
Zeiss Microimaging (Jena, Germany). 
RNAscope analysis
RNAscope staining was analyzed using CellProfiler 
image analysis software (http://www.cellprofiler.
org/) [24]. The pipeline was previously optimized for 
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meningioma TMAs (http://cellprofiler.org/examples/
published_pipelines.html) [23]. Briefly, the image was 
split into hematoxylin and DAB immunopositive layers 
with the “Unmixcolors” module. Then, the background 
was removed and the DAB staining spots were highlighted 
with the “EnhanceOrSuppressFeatures” module. Finally, 
the relation of spots with their host cells was identified 
with the “RelateObjects” module. Optimization for 
the scoring of pituitary tumors was accomplished by 
adjustment of the threshold for detecting nuclei and in 
situ hybridization signals (dots). The average number of 
dots per cell in each pituitary case was compared across 
groups. False positive recognition of stromal cells such 
as blood cells in regions of hemorrhage as well as dark 
staining of some nuclei by the counterstain were excluded 
by visual review. Cases with staining artifacts or poor 
tissue integrity following hybridization processing were 
excluded.
Immunohistochemistry
Pituitary TMA slides were baked at 60°C for one 
hour to melt excess paraffin. Immunohistochemistry 
(IHC) staining for CD3 (1:250, Dako, Carpinteria, CA), 
CD4 (1:80, Dako, Carpinteria, CA), CD8 (1:100, Dako, 
Carpinteria, CA), CD45 (1:50, Dako, Carpinteria, CA), 
PD-L1 (courtesy of Gordon Freeman and validated 
previously [23], 1:125, diluted in Ventana diluent) and 
PD-1 (courtesy of Gordon Freeman, 1:1000, diluted in 
Bond diluent) was performed on a Bond III automated 
IHC stainer using the Bond Refine Detection Kit (Leica 
Biosystems, Buffalo Grove, IL). Antigen retrieval was 
performed using Bond Epitope Retrieval 2 system for 
30 minutes. Tissue stained for PD-L1 used an optimized 
protocol for PD-L1 that consisted of two hour primary 
antibody incubation, while tissue stained for PD-1 and 
CDs utilized an optimized protocol that consisted of a 30 
min primary antibody incubation. Slides were dehydrated 
in 85-100% ethanol, mounted using xylene, and cover-
slipped. All slides were digitally scanned using Carl Zeiss 
Microimaging (Jena, Germany). 
Murine B cells transfected with human PD-L1 gene 
served as a positive control for PD-L1 IHC antibody 
testing (Supplementary Figure 2A-B). Human tonsil 
tissue are known to harbor robust PD-1 protein expression 
within germinal centers, but not outside of them, and 
served as the control tissue for PD-1 IHC antibody testing 
(Supplementary Figure 2C).
Immunohistochemical quantification
Histochemical staining was quantified by color 
deconvolution as previously described [25]. The TMA 
IHC images were split into single case images and 
analyzed using NIH Image J software (http://imagej.
nih.gov/ij/). Single DAB stained images were obtained 
using color deconvolution. After adjustment of the color 
threshold, the intensity of the DAB positive staining was 
measured. A mean value (intensity/area) was used for 
statistical analysis. PD-L1 IHC staining intensity was 
also measured using color deconvolution and quantified 
by Image J. PD-1 and CDs IHC staining were quantified 
by blinded counting. Cases with staining artifacts or 
poor tissue integrity following immunohistochemical 
processing were excluded.
Statistical analysis
Results are expressed as median ± interquartile 
range, within minimum to maximal values. Statistical 
analysis was performed using GraphPad Prism (GraphPad, 
La Jolla, CA), and comparisons were made using unpaired 
Mann-Whitney test. A p value < 0.05 was considered 
significant.
Abbreviations
ACTH, adrenocorticotropic hormone; CTLA-
4, cytotoxic T-lymphocyte-associated protein 4; DAB, 
3, 3’-Diaminobenzidine; FSH, follicle-stimulating 
hormone; GH, growth hormone; IFNγ, interferon-γ; 
IHC, immunohistochemistry; LH, luteinizing hormone; 
PD-1, programmed cell death-1; PD-L1, programmed 
death-ligand 1; PRL, prolactin; TIL, tumor infiltrating 
lymphocyte; TMA, tissue microarray; TSH, thyroid-
stimulating hormone.
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